BP-C1 in the treatment of patients with stage IV breast cancer: a randomized, double-blind, placebo-controlled multicenter study and an additional open-label treatment phase

Stig Larsen, Kritiya Butthongkomvong, Alexey Manikhas, Ekaterina Trishkina, Elena Poddubuskaya, Marina Matrosova, Vichien Srimuninnimit, Steen Lindkær-Jensen, Stig Larsen, Kritiya Butthongkomvong, Alexey Manikhas, Ekaterina Trishkina, Elena Poddubuskaya, Marina Matrosova, Vichien Srimuninnimit, Steen Lindkær-Jensen

Abstract

The aims were to compare the efficacy and tolerability of a new benzene-poly-carboxylic acids complex with cis-diammineplatinum (II) dichloride (BP-C1) versus placebo and to investigate the long-term tolerability of BP-C1 in the treatment of patients with metastatic breast cancer.

Material and methods: A randomized, double-blind, placebo-controlled multicenter study was performed with a semi-crossover design. Patients allocated to placebo switched to BP-C1 after 32 days of treatment. Patients who completed 32 days of BP-C1 treatment were offered the opportunity to continue on BP-C1 for an additional 32 days in an open-label extension. Patients were then followed up for another 28 days. Thirty patients were given daily intramuscular injections of 0.035 mg/kg of body weight BP-C1 or placebo for 32 days. Biochemistry, hematology, National Cancer Institute Common Terminology Criteria for Adverse Events (CTC-NCI), European Organisation for Research and Treatment of Cancer quality of life questionnaire (QOL-C30 and the breast-cancer-specific BR23) data were recorded at screening and after every 16 days of treatment. Computed tomography was performed at screening and every 32 days.

Results: The sum of target lesions increased 2.4% in the BP-C1 group and 14.3% in the placebo group. Only the increase in the placebo group was significant (P=0.013). The difference between the groups was significant in favor of BP-C1 (P=0.04). There was a significant difference (P=0.026) in favor of BP-C1 regarding Response Evaluation Criteria In Solid Tumors (RECIST) classification. The sum of lesions increased slightly in the patients receiving 64 days of continuous BP-C1 treatment, of whom 68.4% were classified as responders. The sum CTC-NCI toxicity score increased nonsignificantly in the BP-C1 group but significantly in the placebo group (P=0.05). The difference in increase between groups did not meet the level of significance (P=0.12). The sum toxicity score was reduced in the patients receiving 64 days of BP-C1 from 9.2 at screening to 8.9 at Day 48, but it increased again to 10.1 by Day 64 and 10.6 during the 28-day follow-up. "Breast cancer-related pain and discomfort" and "Breast cancer treatment problem last week" were significantly reduced (P=0.02) in the BP-C1 group but increased slightly in the placebo group; between-group differences were significant in favor of BP-C1 (P=0.05). "Breast cancer related pain and discomfort", "Breast cancer treatment problem last week," and "Physical activity problem" were significantly reduced during the 64 days of BP-C1 treatment (P≤0.05).

Conclusion: For patients suffering from stage IV metastatic breast cancer, treatment with BP-C1 reduces cancer growth, is well tolerated, improves quality of life, and produces few adverse events, which were mainly mild and manageable.

Keywords: few transient adverse effects; improved Quality of Life; safe; tumor growth reduction.

Figures

Figure 1
Figure 1
Study design. Notes: The blue ellipsoids illustrate the strata and open circles indicate randomization. The colored rectangles illustrate the treatment procedure. Abbreviations: BP-C1, benzene-poly-carboxylic acids complex with cis-diammineplatinum (II) dichloride; R, randomization.
Figure 2
Figure 2
The development in sum of the largest diameters of target lesions, in millmeters. Notes: Results are expressed by mean values with 95% confidence intervals illustrated by columns. The green bars show BP-C1, the yellow bars show placebo, and the blue bar shows results after 28 days of follow-up. (A) BP-C1 versus placebo followed by BP-C1 treatment. (B) Extended 64 days of BP-C1 treatment. Abbreviation: BP-C1, benzene-poly-carboxylic acids complex with cis-diammineplatium (II) dichloride.
Figure 3
Figure 3
The development in sum of National Cancer Institute Common Terminology Criteria for Adverse Events score. Notes: Results are expressed by mean values with 95% confidence intervals illustrated by bars. The green bars show BP-C1, the yellow bars show placebo, and the blue bar shows the results after 28 days of follow-up. (A) BP-C1 versus placebo followed by BP-C1 treatment. (B) Extended 64 days of BP-C1 treatment. Abbreviation: BP-C1, benzene-poly-carboxylic acids complex with cis-diammineplatium (II) dichloride.

References

    1. Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thürlimann B, Senn HJ, Panel members Threshold for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer. Ann Oncol. 2009;20(8):1319–1329.
    1. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365(9472):1687–1717.
    1. Ludwig C, Stoelben E, Hasse J. Disease-free survival after resection of lung metastases in patients with breast cancer. Eur J Surg Oncol. 2003;29(6):532–535.
    1. Hoe AL, Royle GT, Taylor I. Breast liver metastases – incidence, diagnosis and outcome. J R Soc Med. 1991;84(12):714–716.
    1. Boogerd W, Hart AA, Tjahja IS. Treatment and outcome of brain metastasis as first site of distant metastasis from breast cancer. J Neurooncol. 1997;35(2):161–167.
    1. Jørgensen CL, Nielsen TO, Bjerre KD, et al. PAM50 breast cancer intrinsic subtypes and effect of gemcitabine in advanced breast cancer patients. Acta Oncol. 2014;53(6):776–787.
    1. Sledge GW, Jr, Loehrer PJ, Sr, Roth BJ, Einhorn LH. Cisplatin as first-line therapy for metastatic breast cancer. J Clin Oncol. 1988;6(12):1811–1814.
    1. Vogel CL, Nabholtz JM. Monotherapy of metastatic breast cancer: a review of newer agents. Oncologist. 1999;4(1):17–33.
    1. Ershler WB. Capecitabine monotherapy: safe and effective treatment for metastatic breast cancer. Oncologist. 2006;11(4):325–335.
    1. Lao J, Madani J, Puértolas T, et al. Liposomal doxorubicin in the treatment of breast cancer patients: a review. J Drug Deliv. 2013;2013:456409.
    1. Tuxen MK, Cold S, Tange UB, Balslev E, Nielsen DL. Phase II study of neoadjuvant pegylated liposomal doxorubicin and cyclophosphamide ± trastuzumab followed by docetaxel in locally advanced breast cancer. Acta Oncol. 2014;53(10):1440–1445.
    1. Shulman LN, Berry DA, Cirrincione CT, et al. Comparison of doxorubicin and cyclophosphamide versus single-agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary nodes: CALGB 40101 (Alliance) J Clin Oncol. 2014;32(22):2311–2317.
    1. Dewi S, Larsen S, Srimuninnimit V, Lu YS, Manuaba T, Lindkaer-Jensen S. Benzene-poly-carboxyli acid complex with cis-diammineplatinum (II) dichloride in the treatment of stage IV breast cancer patients. The Open Breast Cancer Journal. 2013;5:7–15.
    1. Carlsen KH, Kramer J, Fagertun HE, Larsen S. Loratadine and terfenadine in perennial allergic rhinitis. Treatment of nonresponders to the one drug with the other drug. Allergy. 1993;48(6):431–436.
    1. Pocock SJ. Clinical Trials: A Practical Approach. New York, NY: John Wiley & Sons Ltd; 1989.
    1. Altman DG. Practical Statistics for Medical Research. London, UK: Chapman and Hall; 1990.
    1. Agresti A. Categorical Data Analysis. 2nd ed. Hoboken, NJ: John Wiley & Sons; 2002.
    1. Panel on Handling Missing Data in Clinical Trials and Committee on National Statistics, editor. The Prevention and Treatment of Missing Data in Clinical Trials. National Academy Press; 2010. 2011. Conclusions and recommendations; pp. 110–112.
    1. Shao J, Zhong B. Last observation carry-forward and last observation analysis. Stat Med. 2003;22(15):2429–2441.
    1. Tabachnick BG, Fidell LS. Using Multivariate Statistics. 5th ed. Boston, MA: Pearson Education, Inc; 2007.
    1. Poulsen L. Patients with breast cancer are treated at home. Sygeplejersken. 2014;5:78–85.
    1. Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN. Overview of resistance to systemic therapy in patients with breast cancer. Adv Exp Med Biol. 2007;608:1–22.
    1. Perminova IV. Interaction of 3H-Labeled Benzene-Polycarboxylic Acids (BP-Cx-1) with Tumours and Normal Cell Cultures. Report Moscow State University; 2012.
    1. Fares F, Azzam N, Fares B, Larsen S, Lindkaer-Jensen S. Benzene-poly-carboxylic acid complex, a novel anti-cancer agent induces apoptosis in human breast cancer cells. PLoS One. 2014;9(2):e85156.
    1. Kirkin A, Dzhandzhugazyan KN, Fang JJ, Lindkaer-Jensen S. Benzene-poly-carboxylic acids complex with cis-diammineplatinum [II] dichloride [BP-C1], an innovative anti-cancer agent, activates multiple immunological mechanisms of an antitumor response. International Biologics: Target and Therapy. 2014 In press.
    1. Guarneri V, Conte PF. The curability of breast cancer and the treatment of advanced disease. Eur J Nucl Med Mol Imaging. 2004;31(Suppl 1):S149–S161.
    1. Miller AB, Wall C, Baines CJ, Sun P, To T, Narod SA. Twenty five year follow-up for breast cancer incidence and mortality of the Canadian National Breast Screening Study: randomised screening trial. BMJ. 2014;348:g366.
    1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60(5):277–300.
    1. Cheng YC, Ueno NT. Improvement of survival and prospect of cure in patients with metastatic breast cancer. Breast Cancer. 2012;19(3):191–199.
    1. Cameron DA, Gabra H, Leonard RC. Continuous 5-fluorouracil in the treatment of breast cancer. Br J Cancer. 1994;70(1):120–124.
    1. Carey LA, Rugo HS, Marcom PK, et al. TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. J Clin Oncol. 2012;30(21):2615–2623.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅